Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial (NCT05554341)

🧪 Interventions in This Study

• Nilotinib Hydrochloride Monohydrate (DRUG)
• Paclitaxel (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must be enrolled on the ComboMATCH registration protocol (EAY191) at the time of registration to the EAY191-E4 study
2. Patient must be \>= 18 years of age
3. Patient must not have any of the following mutations (as determined by the ComboMATCH registration protocol), which are known to confer sensitivity or resistance to nilotinib monotherapy:
4. KIT: W557R, V559D, V559A, L576P, and K642E
5. PDGFR-alpha: D842V
6. Patient must have disease that can be safely biopsied and agree to a pre-treatment biopsy or have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH registration trial (EAY191)
7. NOTE: The current actionable mutation of interest (aMOI)/actionable alteration list for this treatment trial can be found on the Cancer Trials Support Unit (CTSU) website
8. NOTE: Novel/dynamic aMOI can be submitted for review per the process described in the ComboMATCH registration protocol
9. Patient must be willing to provide blood samples for research purposes
10. Patient must have had at least one prior line of therapy in the metastatic setting
11. Patient must have previously undergone taxane therapy (in the metastatic setting)
12. Patients who previously responded to prior taxane therapy must have received their last dose of taxane therapy within 6 months prior to EAY191-E4 registration and have had no other intervening treatment prior to EAY191-E4 registration

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (124 Sites)

Showing the first 25 of 124 sites.

• University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
• Kingman Regional Medical Center — Kingman, Arizona
• Stanford Cancer Institute Palo Alto — Palo Alto, California
• Presbyterian Intercommunity Hospital — Whittier, California
• UCHealth University of Colorado Hospital — Aurora, Colorado
• UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
• UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
• UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
• University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
• UM Sylvester Comprehensive Cancer Center at Kendall — Miami, Florida
• UM Sylvester Comprehensive Cancer Center at Plantation — Plantation, Florida
• Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
• Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
• Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
• Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
• Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
• Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho
• Advocate Good Shepherd Hospital — Barrington, Illinois
• Illinois CancerCare-Bloomington — Bloomington, Illinois
• Illinois CancerCare-Canton — Canton, Illinois
• Illinois CancerCare-Carthage — Carthage, Illinois
• Centralia Oncology Clinic — Centralia, Illinois
• Northwestern University — Chicago, Illinois
• John H Stroger Jr Hospital of Cook County — Chicago, Illinois
• Advocate Illinois Masonic Medical Center — Chicago, Illinois

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Malignant Solid Neoplasm

• Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations — Seattle, Washington
• Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes — Duarte, California
• Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) — Duarte, California
• Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors — Duarte, California
• Improving Processes of Cancer Care Delivery at a Comprehensive Cancer Center — Houston, Texas

Explore by condition: All Metastatic Malignant Solid Neoplasm clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.